Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21531725 | 0.97 | CYP2C9 (0.50) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL25615359 | 0.91 | CYP2C9 (0.47) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL24141475 | 0.90 | CYP2C9 (0.44) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL24141582 | 0.73 | CYP2C9 (0.42) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL854453 | 0.72 | MEN1 (0.37) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL9570325 | 0.71 | — | — | |
| SCHEMBL8830207 | 0.71 | — | — | |
| SCHEMBL17525630 | 0.71 | MEN1 (0.36) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL17525729 | 0.71 | MEN1 (0.36) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL17525749 | 0.71 | TNKS (0.37) | MEN1POLBKMT2AHSD17B10HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803026-A | Use of glutarimide derivatives for the treatment of diseases associated with abnormal interleukin-6 activity | 瓦伦塔有限责任公司 | 2023-03-14 | — | — | CN | claimed |
| WO-2023249516-A1 | NOVEL CRYSTALLINE FORM OF 1-[2-(1-METHYLIMIDAZOLE-4-YL)ETHYL]PERHYDROAZINE-2,6-DIONE AND PHARMACEUTICAL USE THEREOF | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2023-12-28 | — | — | WO | disclosed |
| WO-2023121519-A1 | USE OF 1-[2-(1-METHYLIMIDAZOLE-4-YL)-ETHYL]PERHYDROAZINE-2,6-DIONE FOR TREATING COVID-19 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2023-06-29 | — | — | WO | disclosed |
| WO-2023113650-A1 | PHARMACEUTICAL COMPOSITION OF 1-[2-(1-METHYLIMIDAZOLE-4-YL)-ETHYL]PERHYDROAZINE-2,6-DIONE FOR TREATING UPPER RESPIRATORY TRACT DISEASES | НЕБОЛЬСИН, Владимир Евгеньевич | 2023-06-22 | — | — | WO | disclosed |
| EP-3722290-B1 | GLUTARIMIDE DERIVATIVE, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING THE GLUTARIMIDE DERIVATIVE | VALENTA INTELLEKT LTD (RU) | 2023-06-21 | — | — | EP | disclosed |
| CN-115803026-A | Use of glutarimide derivatives for the treatment of diseases associated with abnormal interleukin-6 activity | 瓦伦塔有限责任公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115803026-A | Use of glutarimide derivatives for the treatment of diseases associated with abnormal interleukin-6 activity | 瓦伦塔有限责任公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-3725785-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-21 | — | — | EP | disclosed |
| EP-3722290-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-14 | — | — | EP | disclosed |
| EP-3466425-B1 | USE OF GLUTARIMIDE DERIVATIVES IN THE TREATMENT OF EOSINOPHILIC DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2020-10-07 | — | — | EP | disclosed |
| US-20180016254-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016255-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016255-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016254-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-9815814-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) | 2017-11-14 | — | — | US | disclosed |
| US-9815814-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) | 2017-11-14 | — | — | US | disclosed |
| US-20160279114-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUTARIMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF EOSINOPHILIC DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2016-09-29 | — | — | US | disclosed |
| US-20160279114-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUTARIMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF EOSINOPHILIC DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2016-09-29 | — | — | US | disclosed |
| EP-3069720-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLUTARIMIDE DERIVATIVES, AND APPLICATION THEREOF FOR TREATING EOSINOPHILIC DISEASES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2016-09-21 | — | — | EP | disclosed |
| EP-2985282-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2016-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016255-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, NOTUM, CYP11B2 | CYP2C9 302/4885TSHR 4733/4885CYP2C19 168/4885 |
| US-20180016254-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, HADH, GOT2 | CYP2C9 273/4885TSHR 4689/4885CYP2C19 213/4885 |
| US-20160279114-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUTARIMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF EOSINOPHILIC DISEASES | EPX, CMA1, LTC4S | CYP2C9 1050/4885TSHR 4839/4885CYP2C19 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.